 First patient dosed in U.S. phase 1 clinical trial of TJ-CD4BABL111 in patients with advanced or metastatic solid tumors China sites to join the dose expansion part of the study to accelerate TJ- CD4BABL111 development Results of TJ-L14BABL503 preclinical studies accepted for publication in Journal for ImmunoTherapy of Cancer SHANGHAI and GAITHERSBURG, MD., July 1, 2021 PRNewswire -- I-Mab the Company Nasdaq: IMAB, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced multiple advancements in its 4-1BB bispecific antibody portfolio. 